Research is ongoing to better understand the genetic basis of SRNS and to develop targeted therapies. Newer agents, such as selective endothelin receptor antagonists and biologics, are being explored in clinical trials. Advances in genomics and personalized medicine hold promise for more effective and tailored treatment strategies in the future.
